NCT01403896View on ClinicalTrials.gov

Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Malignant Lymphoma, Stem Cell Type
Interventions
DRUG

Plerixafor (Mozobil)

They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am

DRUG

Plerixafor + G-CSF

They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am

Trial Locations (1)

Unknown

Capital Health District Authority, Halifax

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Stephen Couban

OTHER

NCT01403896 - Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor | Biotech Hunter | Biotech Hunter